AOD-9604 acts directly on adipocytes; semaglutide acts on the GLP-1 receptor system. Two entirely different weight-loss research mechanisms.
| Attribute | AOD-9604 | Semaglutide |
|---|---|---|
| Origin | hGH C-terminal fragment | GLP-1 analog |
| Target | Adipocyte lipolysis pathway | GLP-1R |
| Half-life | Short (minutes) | ~7 days |
| Dosing interval (research) | Daily or more frequent | Weekly |
| Trial depth | Narrow published dataset | Deep Phase III+ |
The two compounds are not mechanistic substitutes. Any research design comparing them must control for the very different half-lives and receptor systems.
Research use only. All information on this page is provided strictly for in-vitro and laboratory research reference. Nothing in this article is medical, therapeutic, dosing, or performance advice for human or veterinary use.
